Skip to main content
Kezar Life Sciences, Inc. logo

Kezar Life Sciences, Inc. — Investor Relations & Filings

Ticker · KZR ISIN · US49372L2097 LEI · 549300EV1V8GXBV18004 US Manufacturing
Open in API
Filings indexed 442 across all filing types
Latest filing 2026-05-11 Delisting Announcement
Country US United States of America
Listing US KZR

About Kezar Life Sciences, Inc.

https://kezarlifesciences.com/

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel, first-in-class small molecule therapeutics. The company advances unique protein-targeting approaches designed to inhibit multiple disease-driving cellular pathways and address the limitations of available treatments. Its development pipeline focuses on creating breakthrough therapies for immune-mediated diseases, liver disease, and oncologic disorders.

Recent filings

Filing Released Lang Actions
25-NSE - Kezar Life Sciences, Inc. (0001645666) (Subject)
Delisting Announcement
2026-05-11 English
8-K - Kezar Life Sciences, Inc. (0001645666) (Filer)
M&A Activity Classification · 85% confidence The document is a Form 8‐K Current Report primarily detailing the completion of a tender offer and merger (Item 2.01), change in control, delisting and related corporate governance changes resulting from that acquisition. This is an announcement of a merger/takeover transaction rather than a proxy statement, proxy solicitation or standard tender-offer form (e.g., SC TO-*, Form 425). It thus best fits the M&A Activity category (Code: TAR).
2026-05-11 English
10-Q - Kezar Life Sciences, Inc. (0001645666) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-11 English
10-K/A - Kezar Life Sciences, Inc. (0001645666) (Filer)
Annual Report FY 2025
2026-04-30 English
8-K - Kezar Life Sciences, Inc. (0001645666) (Filer)
Legal Proceedings Report Classification · 95% confidence The document is a detailed separation agreement between an executive and the company, outlining terms of employment termination, severance benefits, equity treatment, release of claims, and other legal obligations. It references a merger transaction but is not itself a merger filing or proxy statement. It does not contain financial statements, earnings data, or regulatory certifications. It is a legal agreement related to employment termination and severance, not a financial report or announcement. Therefore, it fits best under Legal Proceedings Report (LTR) as it deals with legal terms and releases related to employment separation.
2026-04-03 English
SC14D9C - Kezar Life Sciences, Inc. (0001645666) (Subject)
Merger & Acquisition Classification · 100% confidence The document is a Schedule 14D-9 filing, which is a Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934. It relates to a proposed acquisition and tender offer for Kezar Life Sciences, Inc. by Aurinia Pharma U.S., Inc. The document discusses the terms of the merger agreement, the tender offer, and provides legal and procedural information about the acquisition process. It is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to a merger and acquisition transaction. The presence of Schedule 14D-9 and the detailed description of the tender offer and merger clearly indicate this is a Merger & Acquisition related filing. Therefore, the appropriate classification is MA (Merger & Acquisition). The document length and content confirm it is the actual filing, not just an announcement or summary, so it is not RPA or RNS.
2026-03-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.